InterVene is a trailblazing medical device company focused on reshaping the landscape of treating chronic post-thrombotic venous occlusions and obstructions – the severe late term complications arising from deep vein thrombosis and chronic venous insufficiency.
intervene-med.com
Treo Ventures Contact:
Brad H. Vale, PhD, DVM
CONTACT BRAD
Location: Redwood City, CA
intervene-med.com
Treo Ventures Contact:
Brad H. Vale, PhD, DVM
CONTACT BRAD
Location: Redwood City, CA
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $13M
Founded date: 2011
Investors 3
| Date | Name | Website |
| - | LaunchCapi... | launchcapi... |
| 08.01.2025 | Treo Ventu... | treovp.com |
| - | 3x5 Partne... | 3x5partner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.10.2024 | Series A | $13M | - |
Mentions in press and media 8
| Date | Title | Description |
| 08.10.2024 | InterVene Raises $13M in Series A Financing | InterVene, a Redwood City, CA-based clinical-stage medical device company, raised $13M in Series A funding. The round was led by Treo Ventures and existing investor RiverVest Venture Partners. In conjunction with this financing, Brad Vale, ... |
| 07.10.2024 | InterVene, Inc. Announces $13 Million Series A Financing to Advance Recana™ System Through US Market Clearance | - |
| 26.06.2019 | It’s Not All Smooth Sailing for Facebook’s Libra Project: Term Sheet | LIBRA CONCERNS Before Facebook’s Libra project made its public debut, it recruited high-profile backers that would act as its launch partners. They include Visa, Uber, Mastercard, PayPal and Stripe. Paid Content Securing the enterprise with... |
| 25.06.2019 | InterVene Raises $15M in Series B Funding | InterVene Inc., a South San Francisco, CA-based developer of a catheter-based system to correct deep vein valve failure, raised $15m in Series B financing round. The round was led by new investor 3×5 Partners, who was joined by prior invest... |
| 23.03.2015 | InterVene Closes $5.9M in Series A Funding | InterVene Inc., a Mountain View, CA-based developer of a non-implantable, catheter-based, vein valve creation therapy, closed a $5.9m in Series A funding. The round was led by Boston Scientific (NYSE: BSX) with participation from North Texa... |
| 23.03.2015 | Boston Scientific backs startup’s chronic venous insufficiency treatment in $5.9M Series A | InterVene says the condition costs the U.S. healthcare system nearly $1.9 billion. The funding will support a two-stage clinical trial that’ll attempt to show whether the therapy works safely and correctly. “These studies will be the first ... |
| - | InterVene | “InterVene Inc.” |
| - | Boston Scientific backs startup’s chronic venous insufficiency treatment in $5.9M Series A | If veins in the legs don’t work properly, it can be difficult for blood to return to the heart. Blood can start to pool in the legs and lead to skin changes and painful ulceration. The condition, called chronic venous insufficiency, is actu... |